

GLAXOSMITHKLINE PLC  
Form 6-K  
January 09, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending January 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of changes in the interests of Directors, Persons Discharging Managerial Responsibility or Connected Persons in the  
Ordinary shares  
of GlaxoSmithKline plc

in respect of the under-mentioned  
person

s

arising from the purchase of

Ordinary shares

at a price of £

12.82

per Ordinary

s

hare on

8 January 2009

through the Company

,

s ShareReward Plan (

"

the Plan

"

)

which

the under-mentioned persons

entered on 5 October 2001:

|              |                                                                                          |
|--------------|------------------------------------------------------------------------------------------|
| Mr A P Witty | Acquisition of 20<br>Ordinary shares under the Dividend Reinvestment element of the Plan |
|--------------|------------------------------------------------------------------------------------------|

|               |                                                                                              |
|---------------|----------------------------------------------------------------------------------------------|
| Mr J S Heslop | Acqu<br>isition of 20<br>Ordinary shares under the Dividend Reinvestment element of the Plan |
|---------------|----------------------------------------------------------------------------------------------|

|                 |                                                                                          |
|-----------------|------------------------------------------------------------------------------------------|
| Mr S M Bicknell | Acquisition of 20<br>Ordinary shares under the Dividend Reinvestment element of the Plan |
|-----------------|------------------------------------------------------------------------------------------|

|                |                                                                                          |
|----------------|------------------------------------------------------------------------------------------|
| Mr E J Gray    | Acquisition of 20<br>Ordinary shares under the Dividend Reinvestment element of the Plan |
| Mr D Learmouth | Acquisition of 20<br>Ordinary shares under the Dividend Reinvestment element of the Plan |
| Dr D Pulman    | Acquisition of 8<br>Ordinary shares under the Dividend Reinvestment element of the Plan  |
| Mr D S Redfern | Acquisition of 20<br>Ordinary shares under the Dividend Reinvestment element of the Plan |
| Ms C Thomas    | Acquisition of 20<br>Ordinary shares under the Dividend Reinvestment element of the Plan |

The Company and the above-mentioned persons were advised of this information on

9 January 2009

.

This notification relates to a transaction notified in accordance with

Disclosure  
and Transparency

Rule 3.1.4R(1)(a)

.

V A Whyte  
Deputy Company Secretary  
9 January 2009

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: January 09 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc